Claims:

1. A pharmaceutical composition comprising an active substance selected from nicotinic acid; nicotinamide; tryptophan; a compound that converts in the body of an animal or human into nicotinic acid, nicotinamide or tryptophan; nicotinamide adenine dinucleotide (NAD); nicotinamide adenine dinucleotide phosphate (NADP); an intermediate in the biosynthesis of NAD or NADP; a tryptophan dipeptide; or a combination thereof for positively influencing the intestinal microbiota, wherein the pharmaceutical composition releases the active substance for topical efficacy in the terminal ileum, the colon or both.

2. A pharmaceutical composition comprising an active substance selected from nicotinic acid, nicotinamide, tryptophan or a combination thereof for positively influencing the intestinal microbiota, wherein the pharmaceutical composition releases the active substance for topical efficacy in the terminal ileum, the colon or both.

3. The pharmaceutical composition according to claim 1 or 2, for oral administration with delayed release of the active ingredients for specific local effectiveness in the terminal ileum and/or colon.

4. The pharmaceutical composition according to claim 3, formulated for oral administration with delayed release of the active ingredients for specific local effectiveness in the terminal ileum and/or colon.

5. The pharmaceutical composition according to claim 1 or 2, formulated for oral administration with controlled release of the active ingredients for specific local effectiveness in the terminal ileum and/or colon.

6. The pharmaceutical composition according to any one of claims 1 to 5, comprising nicotinamide.

7. The pharmaceutical composition according to any one of claims 1-6, for the oral administration with delayed active substance release for the therapy or prophylaxis of inflammatory diseases of the small intestine and/or diseases of the large intestine and/or for the prophylaxis of colon carcinoma and/or for the therapy or prophylaxis of other diseases that result from changes in the intestinal microbiota and/or an impaired interaction between intestinal microbiota and intestines.

8. The pharmaceutical composition according to any one of claims 1-6, for the neo(rectal) administration in the colon or pouch for the therapy of inflammatory diseases of the large intestine or pouchitis.

9. The pharmaceutical composition according to claim 8, formulated for (neo)rectal administration in the colon or pouch.

10. The pharmaceutical composition according to claim 9, for use in the therapy or prophylaxis of inflammatory diseases of the large intestine or pouchitis.

11. The pharmaceutical composition according to claim 7, characterized in that the oral application is performed with an active substance content of 1 – 3000 mg per finished dosage form.

12. The pharmaceutical composition according to claim 11, characterized in that the oral application is performed with an active substance content of 100 – 1000 mg per finished dosage form.

13. The pharmaceutical composition according to claim 8, characterized in that the rectal application is performed for the local therapy of inflammations in the rectum or pouch.

14. The pharmaceutical composition according to any one of claims 8, 9, 10 and 13, characterized in that the rectal application is performed with an active substance content of 10 – 5000 mg per finished dosage form.

15. The pharmaceutical composition according to any one of claims 1-14, characterized in that acetylsalicylic acid and/or prostaglandin D2 antagonists are contained in addition to nicotinic acid and/or nicotinamide.

16. The pharmaceutical composition according to any of claims1-14,
    (a) for use in the therapy or prophylaxis of inflammatory bowel disease,
    (b) for use in the therapy or prophylaxis of colon carcinoma, or
    (c) for use in the therapy or prophylaxis of diseases of other body organs, which result from changes in the intestinal microbiota and/or an impaired interaction between intestinal microbiota and intestines.

17. The pharmaceutical composition according to claim 16, for use in the therapy or prophylaxis of inflammatory bowel disease.

18. The pharmaceutical composition according to claim 17, wherein the inflammatory bowel disease is ulcerative colitis or Crohn's disease.

19. The pharmaceutical composition according to any of claims 1 - 18, comprising tryptophan dipeptide.

20. The pharmaceutical composition of claim 1 or 2, for use in positively influencing the intestinal microbiota.

21. Use of the pharmaceutical composition of claim 1 or 2, for positively influencing the intestinal microbiota.

Claims:

1. The use of an active substance selected from nicotinic acid; nicotinamide; tryptophan; nicotinic acid esters; nicotinamide adenine dinucleotide (NAD); nicotinamide adenine dinucleotide phosphate (NADP); an intermediate in the biosynthesis of NAD or NADP selected from the group consisting of N-formylkynurenine, L-kynurenine, 3-hydroxy-L-kynurenine, 3-hydroxyanthranilate, 2-amino-3-carboxymuconate semialdehyde, quinolinate, and beta-nicotinate D-ribonucleotide; a tryptophan dipeptide; or a combination thereof for the manufacture of a pharmaceutical composition for positively influencing the intestinal microbiota, wherein the pharmaceutical composition is adapted or formulated for selective release of the active substance for topical efficacy in the terminal ileum, the colon or both.

2. The use according to claim 1 comprising an active substance selected from nicotinic acid, nicotinamide, tryptophan or a combination thereof for the manufacture of a pharmaceutical composition for positively influencing the intestinal microbiota, wherein the pharmaceutical composition is adapted or formulated for selective release of the active substance for topical efficacy in the terminal ileum, the colon or both.

3. The use according to claim 1 or 2, for oral administration adapted or formulated for delayed release of the active ingredients for specific local effectiveness in the terminal ileum and/or colon.

4. The use according to claim 3, formulated for oral administration adapted or formulated for delayed release of the active ingredients for specific local effectiveness in the terminal ileum and/or colon.

5. The use according to claim 1 or 2, formulated for oral administration adapted or formulated for controlled release of the active ingredients over a prolonged period of time for specific local effectiveness in the terminal ileum and/or colon.

6. The use according to any one of claims 1-4, for the oral administration adapted or formulated for delayed active substance release for the therapy or prophylaxis of inflammatory diseases of the small intestine and/or diseases of the large intestine and/or for the prophylaxis of colon carcinoma and/or for the therapy or prophylaxis of diseases that result from changes in the intestinal microbiota and/or an impaired interaction between intestinal microbiota and intestines.

7. The use according to any one of claims 1 to 6, comprising nicotinamide.

8. The use according to claim 1 or 2, formulated for (neo)rectal administration in the colon or pouch.

9. The use according to claim 1 or 2, for therapy or prophylaxis of inflammatory diseases of the large intestine or pouchitis.

10. The use according to claim 1 or 2, formulated for neo(rectal) administration in the colon or pouch, for the therapy of inflammatory diseases of the large intestine or pouchitis.

11. The use according to claim 7, characterized in that the pharmaceutical composition is adapted or formulated for oral application with an active substance content of 1 – 3000 mg per finished dosage form.

12. The use according to claim 11, characterized in that the pharmaceutical composition is adapted or formulated for oral application with an active substance content of 100 – 1000 mg per finished dosage form.

13. The use according to claim 8, characterized in that the pharmaceutical composition is adapted or formulated for rectal application for the local therapy of inflammations in the rectum or pouch.

14. The use according to any one of claims 8, 9, 10 and 13, characterized in that the pharmaceutical composition is adapted or formulated for rectal application with an active substance content of 10 – 5000 mg per finished dosage form.

15. The use according to any one of claims 1-14, characterized in that acetylsalicylic acid and/or prostaglandin D2 antagonists are contained in addition to nicotinic acid and/or nicotinamide.

16. The use according to any of claims 1-14,
    (a) for therapy or prophylaxis of inflammatory bowel disease,
    (b) for therapy or prophylaxis of colon carcinoma, or
    (c) for therapy or prophylaxis of diseases of body organs, which result from changes in the intestinal microbiota and/or an impaired interaction between intestinal microbiota and intestines.

17. The use according to claim 16, for use in the therapy or prophylaxis of inflammatory bowel disease.

18. The use according to claim 17, wherein the inflammatory bowel disease is ulcerative colitis or Crohn's disease.

19. The use according to any of claims 1 - 18, comprising tryptophan dipeptide.